SCM Pharma says demand for specialised contract manufacturing services is growing as the pharma industry focuses on niche indications, biologics and the development of potent medicines.
Outsourcing-Pharma spoke with managing director Dianne Sharpe du at AAPS in New Orleans who said industry efforts to access smaller patient groups means “[Drugmakers] are looking for services… which are specialised niche and medium scale.”
She also stressed the importance of carrying out contract manufacturing near to where trials are being undertaken and predicted that SCM’s European manufacturing base would attract US customers seeking to access the region’s drug market.
However, while establishing SCM’s new US presence and New Jersey-based business development director Thomas Puskar was the primary focus of the firm’s attendance at AAPS, Sharpe also discussed wider global plans.
In particular she highlighted Japan, the world’s second largest pharmaceutical market, as a key area of growth, explaining that SCM’s sterile fill finish offering had attracted much attention during a visit to the country last month .